Aldeyra Therapeutics, Inc. Ratios

Ratios Dec2013 Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin 2,407.50%3,077.63%10,765.49%17,723.09%19,691.49%26,495.48%10,290.17%1,997.32%3,316.47%3,661.22%1,812.39%2,899.50%
EBIT Margin 2,307.52%2,977.63%10,675.39%17,719.79%19,821.77%27,044.49%10,445.43%1,912.67%3,227.11%3,699.90%2,065.91%3,120.95%
EBITDA Margin 2,307.52%2,977.63%10,675.39%17,719.79%19,821.77%27,044.49%10,445.43%1,912.67%3,227.11%3,699.90%2,065.91%3,120.95%
Operating Margin 2,307.52%2,977.63%10,675.39%17,719.79%19,821.77%27,044.49%10,445.43%1,912.67%3,227.11%3,699.90%2,065.91%3,120.95%
Net Margin 9,455.93%3,920.94%10,765.49%17,723.09%19,691.49%26,495.48%10,073.24%1,972.15%3,316.47%3,661.22%1,812.39%2,899.50%
FCF Margin 1,071.16%1,961.74%8,368.09%14,367.80%16,965.28%20,518.90%7,451.20%1,968.99%2,443.24%3,344.17%1,464.02%2,243.16%
Leverage & Solvency
Interest Coverage Ratio -23.08-29.78-106.75-177.20-198.22-270.44-104.45-19.13-32.27-37.00-20.66-31.21
Times Interest Earned -23.08-29.78-106.75-177.20-198.22-270.44-104.45-19.13-32.27-37.00-20.66-31.21
Valuation
Enterprise Value 40.18M65.85M67.28M130.00M217.83M162.41M266.31M232.37M407.58M206.47M297.15M
Market Capitalization 40.18M65.85M67.28M130.00M217.83M162.41M266.31M232.37M407.58M206.47M297.15M
Return Ratios
Return on Sales 24.07%30.78%107.65%177.23%196.91%264.95%100.73%19.72%33.16%36.61%18.12%29.00%